Related Experiment Video
Updated: Mar 28, 2026
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
[Cryptotanshinone down-regulates the expression of VEGF and inhibits angiogenesis in U2OS osteosarcoma cells]
Yameng Xu1, Quanbo Ji2, Qiang Zhang2
1Department of Traditional Chinese Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China.
Objective:
To explore the effect of cryptotanshinone (CTS) on vascular endothelial growth factor (VEGF) expression in U2OS osteosarcoma cells, with a focus on angiogenesis.
Methods:
U2OS osteosarcoma cells cultured in vitro were divided into (20, 40, 80, 160) μmol/L CTS treated groups and control group. Real-time quantitative PCR was performed to detect the expression of VEGF mRNA in U2OS osteosarcoma cells. The VEGF protein level was determined using Western blotting and immunofluorescence cytochemistry. Cell proliferation ability was detected by CCK-8 assay. The tube formation assay in vitro was used to observe the angiogenesis ability.
Results:
CTS inhibited the levels of VEGF mRNA and protein in a dose-dependent manner in U2OS osteosarcoma cells obviously. CCK-8 assay indicated that CTS inhibited the proliferation of U2OS osteosarcoma cells. The tube formation assay in vitro revealed that CTS inhibited the angiogenesis ability.
Conclusion:
CTS could down-regulate the expression of VEGF and inhibit angiogenesis in U2OS osteosarcoma cells.
Insights
Cryptotanshinone (CTS) inhibits vascular endothelial growth factor (VEGF) in osteosarcoma cells, reducing both cell proliferation and angiogenesis. This study explores CTS's anti-cancer potential by examining its effects on VEGF expression and related cellular functions.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Osteosarcoma is a primary bone malignancy with significant angiogenesis.
- Vascular Endothelial Growth Factor (VEGF) plays a crucial role in tumor angiogenesis and progression.
- Cryptotanshinone (CTS) is a compound with potential anti-cancer properties.
Purpose of the Study:
- To investigate the impact of CTS on VEGF expression in U2OS osteosarcoma cells.
- To evaluate the effect of CTS on angiogenesis in vitro.
- To assess CTS's influence on osteosarcoma cell proliferation.
Main Methods:
- U2OS osteosarcoma cells were treated with varying concentrations of CTS (20-160 μmol/L).
- VEGF mRNA and protein levels were quantified using Real-time quantitative PCR and Western blotting/immunofluorescence.
- Cell proliferation was assessed via CCK-8 assay, and angiogenesis was evaluated using a tube formation assay.
Main Results:
- CTS significantly inhibited VEGF mRNA and protein expression in a dose-dependent manner.
- CTS demonstrated a dose-dependent inhibition of U2OS cell proliferation.
- In vitro tube formation assays confirmed that CTS suppresses angiogenesis.
Conclusions:
- Cryptotanshinone effectively down-regulates VEGF expression in osteosarcoma cells.
- CTS inhibits angiogenesis and cell proliferation in U2OS osteosarcoma.
- CTS shows promise as a therapeutic agent targeting angiogenesis in osteosarcoma.
